Clinical Trial Update: Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating nimotuzumab in combination with concurrent chemoradiotherapy for high-risk nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING